Onyx Pharma (ONXX) Enters $300M+ License Agreement With Ono In Japan

Article Stock Quotes (1) Comments (0)

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) licensed carfilzomib and ONX 0912 to Ono Pharmaceutical Co., Ltd. in Japan in a transaction that is estimated to exceed $300 million.

Ono will be given exclusive rights to develop and commercialize both compounds for all oncology indications in Japan.

Onyx will retain rights in other Asian contries and the world, including the U.S. and Europe.

Carfilzomib is a highly selective proteasome inhibitor and is currently being evaluated in multiple clinical trials for the treatment of patients with multiple myeloma and other cancers.

ONX 0912 in an oral proteasome inhibitor and is currently in Phase 1 testing.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
• Cardiovascular Systems (CSII) ORBIT II Trial Met Endpoints
• Tessera (TSRA), Starboard Reach Agreement Over Board Composition

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?